Shenzhen Salubris Pharm: Market Snapshot and Context
On Thursday 22 October 2026, the Shenzhen Salubris Pharm (002294.SZ) share traded unchanged, with a 0 % price change over the 24‑hour period concluding at 08:39 AM Central European Time. At the time of reporting, one share was priced at approximately CNY 30.02 on the most liquid exchanges. With a circulating supply of roughly 1.1 billion shares, the company’s market capitalization stands at approximately CNY 34.9 billion.
Trading Activity
In the preceding 24 hours, about CNY 332.4 million worth of Shenzhen Salubris Pharm shares exchanged hands. Relative to the previous month’s close, the stock has risen 1.15 %. The 200‑day simple moving average currently sits at CNY 32.87, indicating that the share price is trading below its recent multi‑month average.
Historical Price Extremes
The most recent high for Shenzhen Salubris Pharm over the past year was CNY 70.99 on 2 April 2026, while the 52‑week low reached CNY 29.25 on 22 June 2026. The current price of CNY 30.02 sits just above the low, suggesting a modest upward trajectory from the trough of the previous year.
Comparative Performance of Peer Stocks
The following table summarizes the performance of a selected set of peer companies over the same 24‑hour window, all of which recorded a 0 % change in price:
| Stock | Current Price (CNY) | Market Capitalisation (CNY bn) | Price‑to‑Earnings Ratio |
|---|---|---|---|
| Yangzhou Yangjie Electronics (300373.SZ) | 77.18 | 41.8 | 29.34 |
| Cnooc Energy & (600968.SS) | 3.92 | 41.2 | 10.34 |
| Shanghai Putailai New Energy (603659.SS) | 18.85 | 41.4 | 13.52 |
| Gan & Lee (603087.SS) | 67.6 | 41.2 | 39.9 |
| Changjiang Securities L (000783.SZ) | 7.43 | 41.8 | 8.51 |
These figures illustrate the breadth of valuation metrics within the sector, with price‑to‑earnings ratios ranging from a low of 8.51 to a high of 39.9.
Company Profile
Shenzhen Salubris Pharmaceuticals Co., Ltd. is a health‑care firm headquartered in Shenzhen, China. The company specializes in the research, development, manufacturing, and distribution of pharmaceutical products, including tablets, capsules, injectable formulations, and active pharmaceutical ingredients. Its product portfolio serves both domestic and international markets, positioning the company as a versatile player in the pharmaceutical supply chain.
Analysis
The flat trading day for Shenzhen Salubris Pharm and its peers suggests a period of consolidation following a modest uptrend. While the share price remains below the 200‑day moving average, its proximity to the 52‑week low may indicate that further upside could be possible should market sentiment shift. Investors should monitor upcoming earnings releases and regulatory developments, particularly in the Chinese pharmaceutical sector, to assess whether the current valuation aligns with future growth prospects.
